
1. mem inst oswaldo cruz. 2013 feb;108(1):98-105.

cross-reactive anti-pfclag9 antibodies sera asymptomatic parasite
carriers plasmodium vivax.

costa jd(1), zanchi fb, rodrigues fl, honda er, katsuragawa th, pereira db,
taborda rl, tada ms, ferreira rde g, pereira-da-silva lh.

author information: 
(1)centro de pesquisa em medicina tropical, porto velho, ro, brasil.
joanadarcneves@hotmail.com

the pfclag9 extensively studied immunogenicity. thereby,
the gene product important therapeutics interventions potential
vaccine candidate. antibodies synthetic peptides corresponding to
selected sequences plasmodium falciparum antigen pfclag9 found in
sera falciparum malaria patients rond√¥nia, brazilian amazon. much 
higher antibody titres found semi-immune immune asymptomatic parasite
carriers subjects suffering clinical infections, corroborating original
findings papua guinea. however, sera plasmodium vivax patients the
same amazon area, particular asymptomatic vivax parasite carriers,
reacted strongly peptides. bioinformatic analyses revealed regions 
of similarity p. falciparum pfclag9 p. vivax ortholog pvclag7.
indirect fluorescent microscopy analysis showed antibodies pfclag9
peptides elicited balb/c mice react human red blood cells (rbcs) infected
with p. falciparum p. vivax parasites. patterns reactivity the
surface parasitised rbcs similar. present observations
support previous findings pfclag9 may target protective immune
responses raises possibility cross reactive antibodies to
pvclag7 mixed infections play role regulate fate plasmodium mixed 
infections.

doi: 10.1590/s0074-02762013000100016 
pmcid: pmc3974312
pmid: 23440122  [indexed medline]

